The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5

Keyphrases

• Aldehyde Oxidase 100%
• Allopurinol 33%
• Autism 33%
• Biaryl Ether 66%
• Biotransformation 100%
• Developmental Disorders 33%
• Extravascular 33%
• Fragile X Syndrome 33%
• Hepatic Clearance 66%
• Hepatocytes 33%
• High Clearance 33%
• Hydroxylase 66%
• In Vitro-in Vivo Correlation (IVIVC) 33%
• In Vivo Data 33%
• Labeled Water 33%
• Liver S9 33%
• Metabolism 33%
• Metabolite M1 33%
• Metabotropic Glutamate Receptor 5 (mGluR5) 100%
• Molybdenum Hydroxylases 33%
• Monkey 33%
• Negative Allosteric Modulation 33%
• Negative Allosteric Modulator 100%
• Nicotinamide Adenine Dinucleotide Phosphate (NADPH) 33%
• Nonhuman Primate 33%
• Plasma Clearance 66%
• Raloxifene 33%
• Rat Liver 33%
• Rat Liver S9 33%
• Rodent Models 33%
• Secondary Metabolites 33%
• Selective Inhibition 33%
• Short Half-life 33%
• Subcellular Fractions 33%
• Therapeutic Strategies 33%
• Xanthine Oxidase 100%
• Xanthine Oxidase Inhibitor 33%

Biochemistry, Genetics and Molecular Biology

• Aldehyde Oxidase 100%
• Allopurinol 33%
• Alpha Oxidation 33%
• Biotransformation 100%
• Cell Fractionation 33%
• Haplorhini 33%
• Hepatic Clearance 66%
• Hepatocyte 33%
• Metabolic Pathway 33%
• Metabolite 66%
• Metabotropic Glutamate Receptor 100%
• Metabotropic Receptor 100%
• Oxygenase 100%
• Plasma Clearance 66%
• Raloxifene 33%
• Secondary Metabolite 33%
• Xanthine Oxidase 100%
• Xanthine Oxidase Inhibitor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Aldehyde Oxidase 100%
• Allopurinol 33%
• Allosteric Modulator 100%
• Developmental Disorder 33%
• Fragile X Syndrome 33%
• Haplorhini 33%
• Lead Compound 33%
• Metabotropic Receptor 100%
• Oxidoreductase Inhibitor 33%
• Oxygen 18 66%
• Oxygenase 100%
• Raloxifene 33%
• Reduced Nicotinamide Adenine Dinucleotide Phosphate 33%
• Xanthine Oxidase 100%
• Xanthine Oxidase Inhibitor 33%